Articles
-
4 days ago |
fiercepharma.com | Eric Sagonowsky
Only a few days after reports emerged that the director of the FDA's cell and gene therapy office had been abruptly put on administrative leave, a new departure shows that an intense period of leadership turnover at the agency isn't over. On Monday, Jacqueline Corrigan-Curay, the acting director of the Center for Drug Evaluation and Research (CDER), wrote in an email to colleagues that she'd be retiring from the agency in July, according to reports in Bloomberg, Endpoints News and Stat.
-
1 week ago |
fiercepharma.com | Fraiser Kansteiner |Zoey Becker |Eric Sagonowsky |Angus Liu
-
2 weeks ago |
fiercepharma.com | Eric Sagonowsky
Amid the threat of pharmaceutical tariffs from President Donald Trump, recent months have seen multibillion-dollar U.S. spending pledges from some of the world's largest pharmaceutical companies.
-
2 weeks ago |
fiercepharma.com | Eric Sagonowsky
Right after Robert F. Kennedy Jr. secured confirmation as U.S. health secretary, a postponed CDC expert meeting on vaccines raised concerns among many about the potential changes in store for the nation's vaccine infrastructure. But none of those concerns could adequately capture what the long-time vaccine skeptic—now the top U.S. healthcare official—had in mind.
-
3 weeks ago |
fiercepharma.com | Eric Sagonowsky
Despite uncertainties arising from new FDA policies around COVID-19 vaccines, Moderna has cleared the agency's desk with its next-gen shot, mNEXSPIKE. The FDA has signed off on the company's new COVID-19 vaccine for use in all adults 65 and older, as well as in individuals ages 12 to 64 who have one or more underlying risk factor for severe COVID, such as asthma, diabetes or COPD, Moderna said in a Saturday, May 31 press release.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 603
- Tweets
- 640
- DMs Open
- No
Join me at the Fierce Biotech Summit held in Boston on October 16-18th, where senior executives, thought leaders and investors come together to discuss the future of biotech. https://t.co/7n0BUrZpnP #FierceBiotechSummit #WeAreFierce #FierceEvents #FierceBiotech #Fierce15
RT @FiercePharma: For the first time since 2016, our Fierce team is highlighting the top 10 most productive biopharma companies. Let us tel…
RT @FiercePharma: Our Fierce podcast team is proud to be featured in the 2022 Folio Eddie & Ozzie awards, earning an honorable mention for…